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Background: Therapy with stem cells with potential to regenerate damaged myocardium is an emerging treatment modality for patients with 
coronary artery disease (CAD). This is the first study to demonstrate long term effects of intramyocardial mesenchymal stromal cells (MSC) Treatment. 
We have assessed long-term safety and efficacy of electromechanical guided myocardial injections of autologous bone-marrow derived MSCs in 
patients with severe stable CAD and refractory angina.
Methods: Thirty-one patients with stable CAD, refractory angina and Canadian Cardiovascular Society (CCS) Class II-III were included. Patients had 
reversible myocardial ischemia on adenosine stress single photon emission computerized tomography and no further conventional revascularization 
options. Bone-marrow MSCs were isolated and culture expanded for 6-8 weeks and stimulated with vascular endothelial growth factor to facilitate 
endothelial differentiation. The MSCs were injected into an ischemic, viable region of the myocardium using the electromechanical NOGA® system. 
Patients were followed for 24 months.
Results: Significant and sustained clinical improvements were found at 24 months follow-up. Exercise time had increased from 6:23±1:43 to 
7:02±2:16 minutes (p=0.005) and maximal metabolic equivalent (MET) from 4.23±0.7 to 4.71±1.1 (p=0.004). Angina (CCS class) improved from 
3.0±0.3 to 1.1±1.0 (p< 0.001). The weekly number of angina pectoris attacks was reduced from 13.8±13.7 to 3.2±6.5 (p< 0.001) and weekly use 
of nitroglycerine was reduced from 10.7±10.0 to 3.4±5.2 (p< 0.001). There were significant improvements in all parameters of the Seattle Angina 
Questionnaire (p< 0.001 for all). No early or late side-effects of the treatment were observed.
Conclusions: Long term follow-up data after direct intramyocardial injection of autologous MSCs, in patients with severe CAD and refractory 
angina, demonstrated sustained and significantly positive clinical effects and excellent safety.
